{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:23:00Z","timestamp":1772824980777,"version":"3.50.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s11899-016-0299-0","type":"journal-article","created":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T21:33:03Z","timestamp":1455226383000},"page":"52-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents"],"prefix":"10.1007","volume":"11","author":[{"given":"Joseph","family":"Maly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S.","family":"Blachly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,11]]},"reference":[{"key":"299_CR1","unstructured":"Howlader NNA, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, et al. SEER cancer statistics factsheets: chronic lymphocytic leukemia, in SEER cancer statistics review, 1975\u20132012, N.C. Institute, Editor. 2015, National Cancer Institute. Bethesda MD: seer.cancer.gov ."},{"issue":"1","key":"299_CR2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","volume":"49","author":"P Thurmes","year":"2008","unstructured":"Thurmes P et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49(1):49\u201356.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"299_CR3","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1083\/jcb.121.5.1121","volume":"121","author":"JK Bubien","year":"1993","unstructured":"Bubien JK et al. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol. 1993;121(5):1121\u201332.","journal-title":"J Cell Biol"},{"issue":"21","key":"299_CR4","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-09-1234","volume":"15","author":"MI Vega","year":"2009","unstructured":"Vega MI et al. Rituximab-mediated cell signaling and chemo\/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res. 2009;15(21):6582\u201394.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"299_CR5","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.175.6.1511","volume":"175","author":"CJ Noesel Van","year":"1992","unstructured":"Van Noesel CJ et al. Comparison of human B cell antigen receptor complexes: membrane-expressed forms of immunoglobulin (Ig)M, IgD, and IgG are associated with structurally related heterodimers. J Exp Med. 1992;175(6):1511\u20139.","journal-title":"J Exp Med"},{"issue":"6","key":"299_CR6","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","volume":"120","author":"JA Woyach","year":"2012","unstructured":"Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175\u201384.","journal-title":"Blood"},{"issue":"2","key":"299_CR7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nri726","volume":"2","author":"SK Pierce","year":"2002","unstructured":"Pierce SK. Lipid rafts and B-cell activation. Nat Rev Immunol. 2002;2(2):96\u2013105.","journal-title":"Nat Rev Immunol"},{"key":"299_CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-230X(01)83004-9","volume":"83","author":"FK Stevenson","year":"2001","unstructured":"Stevenson FK et al. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res. 2001;83:81\u2013116.","journal-title":"Adv Cancer Res"},{"issue":"13","key":"299_CR9","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2002-06-1683","volume":"100","author":"L Chen","year":"2002","unstructured":"Chen L et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100(13):4609\u201314.","journal-title":"Blood"},{"issue":"3","key":"299_CR10","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2002-06-1822","volume":"101","author":"S Lanham","year":"2003","unstructured":"Lanham S et al. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101(3):1087\u201393.","journal-title":"Blood"},{"issue":"3","key":"299_CR11","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1182\/blood-2005-12-4986","volume":"108","author":"MI Principe Del","year":"2006","unstructured":"Del Principe MI et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood. 2006;108(3):853\u201361.","journal-title":"Blood"},{"issue":"8","key":"299_CR12","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1128\/MCB.22.8.2524-2535.2002","volume":"22","author":"S Kabak","year":"2002","unstructured":"Kabak S et al. The direct recruitment of BLNK to immunoglobulin alpha couples the B-cell antigen receptor to distal signaling pathways. Mol Cell Biol. 2002;22(8):2524\u201335.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"299_CR13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1084\/jem.188.1.93","volume":"188","author":"VW Chan","year":"1998","unstructured":"Chan VW et al. The molecular mechanism of B cell activation by toll-like receptor protein RP-105. J Exp Med. 1998;188(1):93\u2013101.","journal-title":"J Exp Med"},{"issue":"6","key":"299_CR14","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.3109\/10428194.2012.736983","volume":"54","author":"YH Wang","year":"2013","unstructured":"Wang YH et al. Expression levels of Lyn, Syk, PLCgamma2 and ERK in patients with chronic lymphocytic leukemia, and higher levels of Lyn are associated with a shorter treatment-free survival. Leuk Lymphoma. 2013;54(6):1165\u201370.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"299_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjh.13065","volume":"167","author":"JS Blachly","year":"2014","unstructured":"Blachly JS, Baiocchi RA. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma. Br J Haematol. 2014;167(1):19\u201332.","journal-title":"Br J Haematol"},{"key":"299_CR16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1034\/j.1600-065X.2000.00601.x","volume":"176","author":"MR Gold","year":"2000","unstructured":"Gold MR et al. Targets of B-cell antigen receptor signaling: the phosphatidylinositol 3-kinase\/Akt\/glycogen synthase kinase-3 signaling pathway and the Rap1 GTPase. Immunol Rev. 2000;176:47\u201368.","journal-title":"Immunol Rev"},{"issue":"2","key":"299_CR17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","volume":"72","author":"S Tsukada","year":"1993","unstructured":"Tsukada S et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72(2):279\u201390.","journal-title":"Cell"},{"issue":"3","key":"299_CR18","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/1074-7613(95)90114-0","volume":"3","author":"WN Khan","year":"1995","unstructured":"Khan WN et al. Defective B cell development and function in Btk-deficient mice. Immunity. 1995;3(3):283\u201399.","journal-title":"Immunity"},{"issue":"10","key":"299_CR19","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1084\/jem.191.10.1745","volume":"191","author":"JB Petro","year":"2000","unstructured":"Petro JB et al. Bruton\u2019s tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med. 2000;191(10):1745\u201354.","journal-title":"J Exp Med"},{"issue":"8","key":"299_CR20","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.leu.2403398","volume":"18","author":"S Cuni","year":"2004","unstructured":"Cuni S et al. A sustained activation of PI3K\/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004;18(8):1391\u2013400.","journal-title":"Leukemia"},{"issue":"4","key":"299_CR21","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.4049\/jimmunol.164.4.2200","volume":"164","author":"RR Furman","year":"2000","unstructured":"Furman RR et al. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000;164(4):2200\u20136.","journal-title":"J Immunol"},{"issue":"9","key":"299_CR22","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1182\/blood-2007-11-125278","volume":"111","author":"S Hewamana","year":"2008","unstructured":"Hewamana S et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008;111(9):4681\u20139.","journal-title":"Blood"},{"issue":"29","key":"299_CR23","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107(29):13075\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"299_CR24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z et al. Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem. 2007;2(1):58\u201361.","journal-title":"ChemMedChem"},{"issue":"23","key":"299_CR25","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SE Herman","year":"2011","unstructured":"Herman SE et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287\u201396.","journal-title":"Blood"},{"issue":"5","key":"299_CR26","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","volume":"119","author":"S Ponader","year":"2012","unstructured":"Ponader S et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182\u20139.","journal-title":"Blood"},{"issue":"1","key":"299_CR27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342. First clinical trial in CLL to demonstrate a safe and durable clinical benefit in patients with both standard and high risk CLL while utilizing this molecular based intervention strategy.","journal-title":"N Engl J Med"},{"issue":"3","key":"299_CR28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323. This phase III clinical trial data led to FDA approval for ibrutinib for relapsed\/refractory CLL.","journal-title":"N Engl J Med"},{"key":"299_CR29","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SJJ, et al. Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the Phase II RESONATE\u2122-17 Trial, in 56th ASH Annual Meeting and Exposition. 2014: San Francisco, CA.","DOI":"10.1182\/blood.V124.21.327.327"},{"key":"299_CR30","doi-asserted-by":"crossref","unstructured":"Burger JA, et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a phase II trial in 40 patients, in 55th ASH Annual Meeting and Exposition. 2013: New Orleans, LA.","DOI":"10.1182\/blood.V122.21.675.675"},{"issue":"24","key":"299_CR31","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286\u201394. Describes why some patients treated with ibrutinib do not respond or stop responding after initially having a clinically meaningful response.","journal-title":"N Engl J Med"},{"issue":"15","key":"299_CR32","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539\u201349.","journal-title":"Blood"},{"key":"299_CR33","doi-asserted-by":"crossref","unstructured":"Byrd JC, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2015. doi: 10.1056\/NEJMoa1509981 .","DOI":"10.1056\/NEJMoa1509981"},{"key":"299_CR34","doi-asserted-by":"crossref","unstructured":"Tam CS. The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed\/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial, in 57th annual meeting & exposition. Orlando, FL: American Society of Hematology; 2015.","DOI":"10.1182\/blood.V126.23.832.832"},{"issue":"13","key":"299_CR35","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1074\/jbc.M114.634683","volume":"290","author":"JR Somoza","year":"2015","unstructured":"Somoza JR et al. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase delta. J Biol Chem. 2015;290(13):8439\u201346.","journal-title":"J Biol Chem"},{"key":"299_CR36","doi-asserted-by":"crossref","unstructured":"Brown JRFR, et al. Final results of a phase I study of idelalisib (GS-1101) a selective inhibitor of PI3K\u03b4, in patients with relapsed or refractory CLL, in 2013 ASCO Annual Meeting. Chicago, IL; 2013.","DOI":"10.1200\/jco.2013.31.15_suppl.7003"},{"key":"299_CR37","doi-asserted-by":"crossref","unstructured":"Zelenetz ADLN, et al. A phase 2 study of idelalisib monotherapy in previously untreated patients \u226565\u00a0years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 2014: 56th ASH Annual Meeting and Exposition.","DOI":"10.1182\/blood.V124.21.1986.1986"},{"issue":"11","key":"299_CR38","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997\u20131007. Article which led to the FDA approval of idelalisib for CLL patients which provides definitive support that inhibition of PI3K molecule is clinically relevant.","journal-title":"N Engl J Med"},{"issue":"5","key":"299_CR39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","volume":"21","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella R et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 2012;21(5):694\u2013708.","journal-title":"Cancer Cell"},{"key":"299_CR40","unstructured":"Stephens DMBK, et al. BI 836826, a novel Fc-engineered antibody in combination with phosphoinositide-3-kinase inhibitor for treatment of high risk chronic lymphocytic leukemia. Blood J. 2014;124(21):642"},{"issue":"4","key":"299_CR41","doi-asserted-by":"crossref","first-page":"908","DOI":"10.18632\/oncotarget.1484","volume":"5","author":"RT Burke","year":"2014","unstructured":"Burke RT et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget. 2014;5(4):908\u201315.","journal-title":"Oncotarget"},{"key":"299_CR42","doi-asserted-by":"crossref","unstructured":"Lanasa MCGM, et al. First-in-human study of AMG 319, a highly selective, small molecule inhibitor of PI3K\u03b4, in adult patients with relapsed or refractory lymphoid malignancies, in 55th ASH Annual meeting and exposition. New Orleans, LA; 2013.","DOI":"10.1182\/blood.V122.21.678.678"},{"key":"299_CR43","doi-asserted-by":"crossref","unstructured":"Flinn IPM, et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-delta, gamma, in patients with chronic lymphocytic leukemia, in ASH annual meeting and exposition. New Orleans, LA; 2013.","DOI":"10.1182\/blood.V122.21.677.677"},{"issue":"24","key":"299_CR44","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2014-07-587279","volume":"124","author":"S Dong","year":"2014","unstructured":"Dong S et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood. 2014;124(24):3583\u20136.","journal-title":"Blood"},{"issue":"21","key":"299_CR45","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood.V122.21.4170.4170","volume":"122","author":"JRDM Brown","year":"2015","unstructured":"Brown JRDM et al. Update on the safety and efficacy of the pan class I PI3K inhibitor SAR245408 (XL147) in chronic lymphocytic leukemia and non-Hodgkin\u2019s lymphoma patients. Blood. 2015;122(21):4170.","journal-title":"Blood"},{"issue":"3","key":"299_CR46","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","volume":"319","author":"S Braselmann","year":"2006","unstructured":"Braselmann S et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006;319(3):998\u20131008.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"299_CR47","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","volume":"114","author":"MP Quiroga","year":"2009","unstructured":"Quiroga MP et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009;114(5):1029\u201337.","journal-title":"Blood"},{"issue":"8","key":"299_CR48","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2013.37","volume":"27","author":"SE Herman","year":"2013","unstructured":"Herman SE et al. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2013;27(8):1769\u201373.","journal-title":"Leukemia"},{"issue":"23","key":"299_CR49","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2010-03-275180","volume":"116","author":"M Suljagic","year":"2010","unstructured":"Suljagic M et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood. 2010;116(23):4894\u2013905.","journal-title":"Blood"},{"issue":"13","key":"299_CR50","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","volume":"115","author":"JW Friedberg","year":"2010","unstructured":"Friedberg JW et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578\u201385.","journal-title":"Blood"},{"issue":"15","key":"299_CR51","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","volume":"125","author":"J Sharman","year":"2015","unstructured":"Sharman J et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015;125(15):2336\u201343. Best data to date with inhibiting Syk tyrosine kinase step of cell signaling.","journal-title":"Blood"},{"issue":"33","key":"299_CR52","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","volume":"104","author":"O Hantschel","year":"2007","unstructured":"Hantschel O et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007;104(33):13283\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"299_CR53","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","volume":"17","author":"PC Amrein","year":"2011","unstructured":"Amrein PC et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2011;17(9):2977\u201386.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"299_CR54","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1182\/blood-2008-03-146704","volume":"112","author":"DY Hallaert","year":"2008","unstructured":"Hallaert DY et al. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood. 2008;112(13):5141\u20139.","journal-title":"Blood"},{"issue":"10","key":"299_CR55","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1182\/blood.V85.10.2870.bloodjournal85102870","volume":"85","author":"A Delmer","year":"1995","unstructured":"Delmer A et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood. 1995;85(10):2870\u20136.","journal-title":"Blood"},{"issue":"15","key":"299_CR56","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/sj.onc.1206425","volume":"22","author":"J Glassford","year":"2003","unstructured":"Glassford J et al. BCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cells. Oncogene. 2003;22(15):2248\u201359.","journal-title":"Oncogene"},{"issue":"5","key":"299_CR57","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1182\/blood-2004-05-1715","volume":"105","author":"L Chen","year":"2005","unstructured":"Chen L et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood. 2005;105(5):2036\u201341.","journal-title":"Blood"},{"issue":"2","key":"299_CR58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1309\/491W-L1TN-UFQX-T61B","volume":"113","author":"I Marschitz","year":"2000","unstructured":"Marschitz I et al. Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques. Am J Clin Pathol. 2000;113(2):219\u201329.","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"299_CR59","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.exphem.2006.07.008","volume":"34","author":"C Campas","year":"2006","unstructured":"Campas C et al. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp Hematol. 2006;34(12):1663\u20139.","journal-title":"Exp Hematol"},{"issue":"11","key":"299_CR60","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin CM et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18(11):3163\u20139.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"299_CR61","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u20138.","journal-title":"Nat Med"},{"issue":"1","key":"299_CR62","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","volume":"117","author":"V Gaizo Moore Del","year":"2007","unstructured":"Del Gaizo Moore V et al. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117(1):112\u201321.","journal-title":"J Clin Invest"},{"issue":"25","key":"299_CR63","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","volume":"124","author":"S Peirs","year":"2014","unstructured":"Peirs S et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738\u201347.","journal-title":"Blood"},{"key":"299_CR64","unstructured":"Roberts AWMS, et al. Venetoclax (ABT-199\/GDC-0199) combined with rituximab induces deep responses in patients with relapsed\/refractory chronic lymphocytic leukemia. 2015: EHA20."},{"issue":"7","key":"299_CR65","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2005-04-1678","volume":"106","author":"R Chen","year":"2005","unstructured":"Chen R et al. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005;106(7):2513\u20139.","journal-title":"Blood"},{"issue":"11","key":"299_CR66","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","volume":"29","author":"IW Flinn","year":"2005","unstructured":"Flinn IW et al. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk Res. 2005;29(11):1253\u20137.","journal-title":"Leuk Res"},{"issue":"11","key":"299_CR67","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1158\/1078-0432.CCR-04-2276","volume":"11","author":"JC Byrd","year":"2005","unstructured":"Byrd JC et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res. 2005;11(11):4176\u201381.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"299_CR68","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","volume":"109","author":"JC Byrd","year":"2007","unstructured":"Byrd JC et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109(2):399\u2013404.","journal-title":"Blood"},{"issue":"35","key":"299_CR69","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2009.22.6944","volume":"27","author":"TS Lin","year":"2009","unstructured":"Lin TS et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009;27(35):6012\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"299_CR70","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","volume":"9","author":"D Parry","year":"2010","unstructured":"Parry D et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010;9(8):2344\u201353.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"299_CR71","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1021\/ml100051d","volume":"1","author":"K Paruch","year":"2010","unstructured":"Paruch K et al. Discovery of Dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med Chem Lett. 2010;1(5):204\u20138.","journal-title":"ACS Med Chem Lett"},{"issue":"12","key":"299_CR72","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/leu.2012.144","volume":"26","author":"AJ Johnson","year":"2012","unstructured":"Johnson AJ et al. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia. 2012;26(12):2554\u20137. Provides data that agents clinically active in CLL through inhibition in the clonal neoplastic cell population also inhibit other mechanisms important for tumor growth.","journal-title":"Leukemia"},{"key":"299_CR73","doi-asserted-by":"crossref","unstructured":"Flynn JMAL, et al. Dinaciclib (SCH 727965) is a novel cyclin-dependent kinase (CDK) inhibitor that exhibits activity in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), in 55th ASH annual meeting and exposition. New Orleans, LA; 2013.","DOI":"10.1182\/blood.V122.21.871.871"},{"issue":"5","key":"299_CR74","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2006-03-011759","volume":"109","author":"S Gobessi","year":"2007","unstructured":"Gobessi S et al. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood. 2007;109(5):2032\u20139.","journal-title":"Blood"},{"key":"299_CR75","doi-asserted-by":"crossref","unstructured":"Dielschneider RF, et al. Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling. Cell Death Dis. 2014;5:e1439.","DOI":"10.1038\/cddis.2014.391"},{"issue":"1","key":"299_CR76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/sj.cdd.4402058","volume":"14","author":"LM Rozan","year":"2007","unstructured":"Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ. 2007;14(1):3\u20139.","journal-title":"Cell Death Differ"},{"issue":"8","key":"299_CR77","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ncb0805-758","volume":"7","author":"ZJ Chen","year":"2005","unstructured":"Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol. 2005;7(8):758\u201365.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"299_CR78","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1039\/c3np20126k","volume":"30","author":"KB Kim","year":"2013","unstructured":"Kim KB, Crews CM. From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. Nat Prod Rep. 2013;30(5):600\u20134.","journal-title":"Nat Prod Rep"},{"issue":"6","key":"299_CR79","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","volume":"121","author":"KM Kortuem","year":"2013","unstructured":"Kortuem KM, Stewart AK. Carfilzomib. Blood. 2013;121(6):893\u20137.","journal-title":"Blood"},{"issue":"9","key":"299_CR80","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1158\/1078-0432.CCR-12-2754","volume":"19","author":"SV Gupta","year":"2013","unstructured":"Gupta SV et al. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-kappaB response in chronic lymphocytic leukemia cells. Clin Cancer Res. 2013;19(9):2406\u201319.","journal-title":"Clin Cancer Res"},{"key":"299_CR81","doi-asserted-by":"crossref","unstructured":"Awan FT, et al. Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma. 2015;56(10)2834\u201340.","DOI":"10.3109\/10428194.2015.1014368"},{"issue":"2","key":"299_CR82","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2014-07-585364","volume":"125","author":"B Lamothe","year":"2015","unstructured":"Lamothe B et al. Proteasome inhibitor carfilzomib complements ibrutinib\u2019s action in chronic lymphocytic leukemia. Blood. 2015;125(2):407\u201310.","journal-title":"Blood"},{"issue":"39","key":"299_CR83","doi-asserted-by":"crossref","first-page":"15454","DOI":"10.1073\/pnas.0702891104","volume":"104","author":"MA Santos","year":"2007","unstructured":"Santos MA et al. Notch1 engagement by delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells. Proc Natl Acad Sci U S A. 2007;104(39):15454\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"299_CR84","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2011.060129","volume":"97","author":"I Giudice Del","year":"2012","unstructured":"Del Giudice I et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica. 2012;97(3):437\u201341.","journal-title":"Haematologica"},{"issue":"2","key":"299_CR85","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2011-10-386144","volume":"119","author":"V Balatti","year":"2012","unstructured":"Balatti V et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood. 2012;119(2):329\u201331.","journal-title":"Blood"},{"issue":"7354","key":"299_CR86","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente XS et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101\u20135.","journal-title":"Nature"},{"issue":"4","key":"299_CR87","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood-2008-02-139725","volume":"113","author":"E Rosati","year":"2009","unstructured":"Rosati E et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113(4):856\u201365.","journal-title":"Blood"},{"issue":"3","key":"299_CR88","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09155.x","volume":"158","author":"D Rossi","year":"2012","unstructured":"Rossi D et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol. 2012;158(3):426\u20139. Provides a potential explanation and target for patients with a type of disease progression that has dismal outcomes.","journal-title":"Br J Haematol"},{"issue":"21","key":"299_CR89","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1182\/blood.V124.21.1972.1972","volume":"124","author":"JLM-CR Klitgaard","year":"2014","unstructured":"Klitgaard JLM-CR et al. Inhibition of the Notch1 pathway in chronic lymphocytic leukemia promotes apoptosis and inhibits proliferation. Blood. 2014;124(21):1972.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0299-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-016-0299-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0299-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T08:32:52Z","timestamp":1600158772000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-016-0299-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["299"],"URL":"https:\/\/doi.org\/10.1007\/s11899-016-0299-0","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}